P/B
—
RedHill Biopharma
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
$3M
Market Cap • 10/5/2026
2009
(17 years)
Founded
2013
(13 years ago)
IPO
NASDAQ
Listing Exchange
Israel
Country
Valuation
P/S
—
P/EBITDA
0,4
P/OCF
—
P/FCF
—
P/E
—
BVPS
—
EPS
0,4
Market Cap
Market Cap
3M
EV
-1,1M
EV/Revenue
0
EV/EBITDA
-0,1
EV/EBIT
-0,1
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-326,2%
Total Yield
-326,2%
Payout
0%
Retained Earnings
-419,2M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
3,9%
Capex/OCF
-0,2%
SBC/OCF
—
% PPE
3,7%
% Goodwill
0%
ROE
64,6%
ROIC
64,3%
Growth
CAGR Revenue 5Y
-100%
CAGR Net Income 5Y
-50,5%
CAGR EPS 5Y
-100%
CAGR OCF 5Y
-29,6%
Leverage
N.D./EBITDA
—
Debt/Equity
0%
Current Ratio
0,3
Quick Ratio
0,2
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!